Prevalence and risk factors of depression in patients with drug-resistant tuberculosis in Nepal: A cross-sectional study

Shrestha, Sailesh Kumar; Joshi, Sulochana; Bhattarai, Ratna Bahadur; Joshi, Lok R.; Adhikari, Nilaramba; Shrestha, Suvesh Kumar; Basnet, Rajendra; Kc, Kedar Narsingh

doi:10.1016/j.jctube.2020.100200

Cited by 9 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A study from India however reported a low prevalence of depression in TB patients 16.2. 14 A study 18 conducted in Nepal reported the prevalence of TB 62.7% which is comparable to our findings.…”

Section: Discussionsupporting

confidence: 90%

Prevalence and Determinants of Depression Among Multi Drug Resistant (MDR) TB Cases

Ayub¹,

Khan²,

Kumari³

et al. 2023

PJMHS

View full text Add to dashboard Cite

Aim: We aimed this study to find the prevalence of depression among multi drug resistant (MDR) TB patients and its related determinants. Material and methods: An observational cross-sectional study was conducted at Jinnah Postgraduate Medical Center Karachi hospital, we enrolled 107 MDR-TB patients using non-probability consecutive sampling. Patients were evaluated for depression using Patient Health Questionnaire-9 (PHQ-9). Prevalence of depression along with its determinant were assessed. We used Chi Square test for association between depression and its determinants keeping P value < 0.05 was taken as statistically significant. Results: Patients’ mean age was 32.10±6.19, male patients were higher in number as compared to female patients. In our study we found that depression was present in 52 (48.6%) patients. Depression had significant association with financial issues, family problems, treatment duration and increasing age. Practical implication: Current study assess the determinants of depression in TB patients and spreads public awareness in community about Multidrug resistance in TB and ways to avoid TB in local population. Conclusion: From our study we conclude that 52 (48.6%) patients had depression in MDR-TB patients which is an alarming situation. Financial issues, family problems, treatment duration and increasing age were found to the determinants of depression in MDR-TB patients. Keywords: Tuberculosis, Multi Drug Resistance, Depression, Truenat, Xpert, Mental disorders, psychiatric comorbidity

show abstract

Section: Discussionsupporting

confidence: 90%

Prevalence and Determinants of Depression Among Multi Drug Resistant (MDR) TB Cases

Ayub¹,

Khan²,

Kumari³

et al. 2023

PJMHS

View full text Add to dashboard Cite

show abstract

“…In our study, the prevalence of depression among people with TB at baseline (end of intensive phase) and follow-up (end of continuation phase) was higher than other cross-sectional studies conducted in Nepal (10%) and China (18%) but similar to Nigeria (28%) and Vietnam (25%) [44,[80][81][82]. The differences in depression prevalence across countries may relate to the time point during TB treatment at which the depression scale was applied and also to sociodemographic differences including urban or rural location, age, gender, inadequate social support, and low education status [83].…”

Section: Depressioncontrasting

confidence: 66%

Stigma, depression, and quality of life among people with pulmonary tuberculosis diagnosed through active and passive case finding in Nepal: a prospective cohort study

Dixit,

Rai,

Aryal

et al. 2024

BMC Global Public Health

View full text Add to dashboard Cite

Background The psychosocial consequences of tuberculosis (TB) are key barriers to ending TB globally. We evaluated and compared stigma, depression, and quality of life (QoL) among people with TB diagnosed through active (ACF) and passive (PCF) case-finding in Nepal. Methods We prospectively recruited adults with TB diagnosed through ACF and PCF in four districts of Nepal between August 2018 and April 2019. Participants were interviewed at 8–12 weeks (baseline) and 22–26 weeks (follow-up) following treatment initiation. TB stigma was measured using an adapted Van Rie Stigma Scale (0 = no stigma to 30 = highest stigma). Depression was measured using a locally-validated Patient Health Questionnaire (PHQ-9). Mild and major depression were indicated by PHQ-9 scores 5–9 and ≥ 10, respectively. QoL was measured using the EuroQoL 5-Dimension 5-level (EQ-5D-5L) from 0 to 1 (optimal QoL); and self-rated health from 0 to 100 (optimal self-rated health). Results We recruited 221 participants (111 ACF; 110 PCF) with a mean age of 48 years (standard deviation [SD] = ± 16), of whom 147/221 (67%) were men. The mean TB stigma score was 12 (SD = 7.3) at baseline and 12 (SD = 6.7) at follow-up. The most commonly perceived elements of TB stigma at baseline were that people with TB experienced guilt (110/221, 50%) and feared disclosure outside their household (114/221, 52%). Self-rated health and EQ-5D-5L scores increased from baseline to follow-up (69.3 to 80.3, p < 0.001; 0.92 to 0.9, p = 0.009). Nearly one-third of participants (68/221, 31%) had mild or major depression at baseline. The proportion of participants with major depression decreased from baseline to follow-up (11.5% vs. 5%, p = 0.012). There was a moderate, significant positive correlation between depression and stigma scores (r = 0.41, p < 0.001). There were no differences found in TB stigma, self-rated health, QoL, or prevalence of mild/major depression between ACF and PCF participants. Conclusions We found a substantial, persistent, and clustered psychosocial impact among adults with TB diagnosed through both ACF and PCF strategies in Nepal. These findings suggest an urgent need to develop effective, evidence-based psychosocial support interventions with the potential to be integrated with existing ACF strategies and routine TB service activities.

show abstract

“…We selected covariates a priori based on previous studies demonstrating that these covariates correlate with prognosis and/or rates of toxicities in aggressive NHL [22][23][24][25][26][27]. We then conducted multivariable logistic regression analyses including all covariates with a value of p < .25 in univariate analyses [28,29]. We included treatment regimen in the multivariable model of grade 3-5 nonhematologic toxicity given the established association of treatment regimen with grade 3-4 adverse events [26].…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma

Johnson

Horick

et al. 2021

The Oncologist

View full text Add to dashboard Cite

Background. Although balancing treatment efficacy with risks of complications is critical for older adults with aggressive non-Hodgkin lymphoma (NHL), few studies have described these patients' clinical outcomes, rates of toxicities, and health care utilization. Methods. We conducted a retrospective analysis of adults ≥65 years diagnosed with aggressive NHL and receiving systemic therapy at Massachusetts General Hospital from April 2000 to July 2020. We abstracted patient characteristics, clinical outcomes, treatment toxicity, unplanned hospitalizations, and intensive care unit (ICU) admissions within 6 months of treatment initiation from the medical record. Using multivariable logistic regression, we examined factors associated with rates of grade 3+ nonhematologic toxicity and unplanned hospitalization. Results. Among 295 patients (median age, 73 years; 39.0% female), 5-year overall survival (OS) was 74.2%. Five-year OS by age group (65-69, 70-74, 75-79, and 80+ years) was

show abstract

Prevalence and risk factors of depression in patients with drug-resistant tuberculosis in Nepal: A cross-sectional study

Cited by 9 publications

References 19 publications

Prevalence and Determinants of Depression Among Multi Drug Resistant (MDR) TB Cases

Prevalence and Determinants of Depression Among Multi Drug Resistant (MDR) TB Cases

Stigma, depression, and quality of life among people with pulmonary tuberculosis diagnosed through active and passive case finding in Nepal: a prospective cohort study

Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma

Contact Info

Product

Resources

About